Armstrong, Paul W.

Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes

Green, J. B., Bethel, M. A., Armstrong, P. W., Buse, J. B., Engel, S. S., Garg, J., Josse, R., Kaufman, K. D., Koglin, J., Korn, S., et al. (2015) · New England Journal of Medicine

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 2,577

The Effects of Climate Change on Cardiac Health

De Blois, J., Kjellstrom, T., Agewall, S., Ezekowitz, J. A., Armstrong, P. W., & Atar, D. (2015) · Cardiology

Climate Change and Health ImpactsThermoregulation and physiological responses

Cited by 1,697

Vericiguat in patients with heart failure and reduced ejection fraction

Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., et al. (2020) · New England Journal of Medicine

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 1,358

Comparative Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure

Packer, M., Poole-Wilson, P. A., Armstrong, P. W., Cleland, J. G. F., Horowitz, J. D., Massie, B. M., Rydén, L., Thygesen, K., & Uretsky, B. F. (1999) · Circulation

Heart Failure Treatment and ManagementHeart rate and cardiovascular health

Cited by 1,244

Prasugrel versus clopidogrel for acute coronary syndromes without revascularization

Roe, M. T., Armstrong, P. W., Fox, K. A. A., White, H. D., Prabhakaran, D., Goodman, S. G., Cornel, J. H., Bhatt, D. L., Clemmensen, P., Martinez, F., et al. (2012) · New England Journal of Medicine

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 874

Anemia Is Common in Heart Failure and Is Associated With Poor Outcomes: Insights From a Cohort of 12 065 Patients With New-Onset Heart Failure

Ezekowitz, J. A., McAlister, F. A., & Armstrong, P. W. (2003) · Circulation

Erythropoietin and Anemia TreatmentHeart Failure Treatment and Management

Cited by 866

Early versus Delayed, Provisional Eptifibatide in Acute Coronary Syndromes

Giugliano, R. P., White, J. A., Bode, C., Armstrong, P. W., Montalescot, G., Lewis, B. S., van `t Hof, A., Berdan, L. G., Lee, K. L., Strony, J. T., et al. (2009) · New England Journal of Medicine

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 506

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

Zannad, F., Garcia, A. A., Anker, S. D., Armstrong, P. W., Calvo, G., Cleland, J. G. F., Cohn, J. N., Dickstein, K., Domanski, M. J., Ekman, I., et al. (2013) · European Journal of Heart Failure

Heart Failure Treatment and ManagementStatistical Methods in Clinical Trials

Cited by 231

Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial

McGuire, D. K., Van de Werf, F., Armstrong, P. W., Standl, E., Koglin, J., Green, J. B., Bethel, M. A., Cornel, J. H., Lopes, R. D., Halvorsen, S., et al. (2016) · JAMA Cardiology

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 217

Cardiovascular Drug Development

Fordyce, C. B., Roe, M. T., Ahmad, T., Libby, P., Borer, J. S., Hiatt, W. R., Bristow, M. R., Packer, M., Wasserman, S. M., Braunstein, N., et al. (2015) · Journal of the American College of Cardiology

Pharmaceutical Economics and PolicyPharmaceutical industry and healthcare

Cited by 202

Transition from meeting abstract to full-length journal article for randomized controlled trials.

Toma, M., McAlister, F. A., Bialy, L., Adams, D., Vandermeer, B., & Armstrong, P. W. (2006) · JAMA

Meta-analysis and systematic reviewsAcademic Publishing and Open Access

Cited by 159

N-Terminal Pro-B-Type Natriuretic Peptide and Clinical Outcomes

Ezekowitz, J. A., O’Connor, C. M., Troughton, R. W., Alemayehu, W. G., Westerhout, C. M., Voors, A. A., Butler, J., Lam, C. S. P., Ponikowski, P., Emdin, M., et al. (2020) · JACC: Heart Failure

Heart Failure Treatment and ManagementCardiac Fibrosis and Remodeling

Cited by 146

Causes of death in a contemporary cohort of patients with type 2 diabetes and atherosclerotic cardiovascular disease: insights from the tecos trial

Sharma, A., Green, J. B., Dunning, A., Lokhnygina, Y., Al-Khatib, S. M., Lopes, R. D., Buse, J. B., Lachin, J. M., Van de Werf, F., Armstrong, P. W., et al. (2017) · Diabetes Care

Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 80

Increased risk of severe hypoglycemic events before and after cardiovascular outcomes in TECOS suggests an at-risk type 2 diabetes frail patient phenotype

Standl, E., Stevens, S. R., Armstrong, P. W., Buse, J. B., Chan, J. C. N., Green, J. B., Lachin, J. M., Scheen, A., Travert, F., Van de Werf, F., et al. (2018) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 76

Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial

Bakal, J. A., Roe, M. T., Ohman, E. M., Goodman, S. G., Fox, K. A. A., Zheng, Y., Westerhout, C. M., Hochman, J. S., Lokhnygina, Y., Brown, E. B., et al. (2015) · European Heart Journal

Statistical Methods in Clinical TrialsAntiplatelet Therapy and Cardiovascular Diseases

Cited by 59

Transfusion and mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention

Jolicœur, E. M., O'Neill, W. W., Hellkamp, A., Hamm, C. W., Holmes, D. R., Al-Khalidi, H. R., Patel, M. R., Van de Werf, F. J., Pieper, K., Armstrong, P. W., et al. (2009) · European Heart Journal

Blood transfusion and managementAcute Myocardial Infarction Research

Cited by 54